Market Cap
$33.4B
BIIB
BIOGEN INC.
$220.62 ▼ -0.99%
Prev close $222.82Market cap$33.4B
ConsensusBuy
12-mo target$238.18 (+8.0%)
▲ Bullish
Analyst conviction 7/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)34 New Institutional Positions16 Institutional ExitsCongressional Activity (1) Biotech & Drug Discovery
Snapshot
The big-picture read on BIIB right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (70%)
Inst. Holders
50 funds
Inst. Value
$26.1B
Inst. Activity
34 buys / 16 sells
Insider Activity
$585.11 buy / $771.3K sell
Insider Net $
-$770.7K
SEC Reports
9
Press Releases
16
Congressional
4 trades
Price chart 30d -0.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 fda
Sep 4, 2026 Press Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced 52-we
Biogen (BIIB) and partner Stoke Therapeutics (STOK) presented positive 4-year open-label extension data for zorevunersen
Impact 4/10
Biogen and Eisai announced that China's NMPA approved the subcutaneous autoinjector formulation of LEQEMBI (lecanemab) f
Impact 7/10
Sep 1, 2026 Insider
Parini Michael was granted 7,405 shares
Chief Legal Officer
Aug 18, 2026 Congress
Kevin Hern sell
$1,001 - $15,000 — House
Aug 4, 2026 Insider
Minor Lloyd sold 593 shares
Director @ $200.96 ($119.2K)
Aug 3, 2026 Insider
Minor Lloyd sold 593 shares
Director @ $203.34 ($120.6K)
Jul 29, 2026 Event
HSR Early Termination: Biogen Inc.; RayThera, Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving Biogen I
Analyst ratings buy % +40.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
70% rate it Buy or better · 43 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 10, 2026 | HSBC | MAINTAIN | Reduce | 55% |
| Sep 3, 2026 | Piper Sandler | REITERATE | Overweight | 54% |
| Aug 25, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Aug 13, 2026 | Wolfe Research | UPGRADE | Outperform | 52% |
| Aug 4, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| Aug 3, 2026 | Citigroup | MAINTAIN | Neutral | 55% |
| Jul 30, 2026 | UBS | MAINTAIN | Buy | 55% |
| Jul 30, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jul 30, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | 55% |
| Jul 30, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 10 | 20 | 12 | 1 | 0 | 70% | |
| Aug 1, 2026 | 9 | 20 | 13 | 1 | 0 | 67% | |
| Jul 1, 2026 | 9 | 19 | 15 | 1 | 0 | 64% | |
| Jun 1, 2026 | 9 | 18 | 16 | 1 | 0 | 61% | |
| May 1, 2026 | 9 | 15 | 18 | 1 | 0 | 56% | |
| Apr 1, 2026 | 9 | 11 | 22 | 1 | 0 | 47% | |
| Mar 1, 2026 | 9 | 11 | 22 | 1 | 0 | 47% | |
| Feb 1, 2026 | 9 | 11 | 21 | 1 | 0 | 48% |
Price targets
Where 31 covering analysts think BIIB trades over the next 12 months.
$238.18 +8.0% upside Buy
Current$220.62 Low$175.00 Median$240.00 High$300.00 31 analysts
$175.00$300.00
Analyst rating Buy· 1.9/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 4 bullish, 0 bearish, 1 mixed, 4 neutral · avg impact 3.3/10.Plus 16 press releases.
BULLISHANALYST-UPGRADE3/10
Truist Securities upgrades BIIB to Buy — PT $235 (+18%)
Jul 13, 2026
BULLISHANALYST-UPGRADE4/10
Wells Fargo double upgrades to Overweight with $250 PT — +41% upside
Apr 20, 2026
MIXEDANALYST-UPGRADE3/10
UBS double upgrades NVDA to Buy — PT $225 (+21%)
Apr 22, 2026
BULLISHANALYST-UPGRADE2/10
Needham upgrades BIIB to Buy — PT $255 (+30.5%)
Jun 8, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
fda
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced 52-week results from the Phase 2 part of the ongoing AM
Sep 28, 2026
short_volume
Short Volume: BIIB — 62.8% short (0.3M / 0.5M)
Short: 315,067 | Exempt: 0 | TRF Vol: 501,596 | Short Ratio: 62.8% | Off-exchange volume (dark pool + OTC)
Sep 17, 2026
fda
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the publication of results from a prespecified adolesc
Sep 16, 2026
other
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive Disease The First and Onl
Sep 9, 2026
Clinical Trial
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.03 | $1.44–$2.67 | -57.8% | -0.3% | 1↑ 20↓ | $2.6B | 26 |
| Next Q | $3.27 | $2.77–$3.87 | 64.3% | +0.1% | 1↑ 1↓ | $2.6B | 26 |
| Current FY | $12.54 | $12.00–$16.39 | -17.9% | +1.0% | 1↑ 2↓ | $10.4B | 33 |
| Next FY | $16.54 | $13.33–$19.29 | 31.9% | -0.0% | 5↑ 1↓ | $10.7B | 33 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.029 | — |
| 7d ago | $2.029 | — |
| 30d ago | $2.035 | -0.006 |
| 60d ago | $2.955 | -0.926 |
| 90d ago | $3.935 | -1.905 |
Institutional ownership
Which big funds own BIIB (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $26.1B total value (120,772,999 shares) as of 2026-Q2. Top holders: FMR, BlackRock,, PRIMECAP. Net buying activity: 34 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 18,217,239 | $3.9B | 15.1% | ADD +42.2% |
| BlackRock, Inc. | 15,985,736 | $3.5B | 13.2% | — |
| PRIMECAP MANAGEMENT CO/CA/ | 15,154,606 | $3.3B | 12.5% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 9,651,117 | $2.1B | 8.0% | — |
| STATE STREET CORP | 7,344,327 | $1.6B | 6.1% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6,604,936 | $1.4B | 5.5% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 4,449,295 | $957.9M | 3.7% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 3,117,469 | $673.6M | 2.6% | — |
| NORGES BANK | 2,580,033 | $557.4M | 2.1% | NEW |
| MORGAN STANLEY | 2,411,271 | $521.0M | 2.0% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FMR LLC | ADD | 12,807,541 | 18,217,239 | +42.2% | $3.9B |
| NORGES BANK | NEW | — | 2,580,033 | — | $557.4M |
| Amundi | ADD | 790,827 | 1,516,831 | +91.8% | $327.7M |
| Boston Partners | TRIM | 1,700,078 | 1,263,429 | -25.7% | $272.8M |
| UBS Group AG | ADD | 523,450 | 1,030,150 | +96.8% | $222.6M |
| CITIGROUP INC | ADD | 500,507 | 734,517 | +46.8% | $158.7M |
| ROYAL BANK OF CANADA | ADD | 531,377 | 708,562 | +33.3% | $153.1M |
| CITADEL ADVISORS LLC | DOUBLED | 138,093 | 418,356 | +203.0% | $90.4M |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 650,046 | 265,090 | -59.2% | $57.3M |
| BARCLAYS PLC | TRIM | 551,474 | 247,157 | -55.2% | $53.4M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
20 insiders, 50 transactions. Net -$770.7K — $585.11 bought, $771.3K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Parini Michael | Chief Legal Officer | AWARD | 7,405 | — | — |
| Aug 4, 2026 | Minor Lloyd | Director | SELL | 593 | $200.96 | $119.2K |
| Aug 3, 2026 | Minor Lloyd | Director | SELL | 593 | $203.34 | $120.6K |
| Jun 9, 2026 | Freire Maria C | Director | AWARD | 2,005 | — | — |
| Jun 9, 2026 | Pangalos Menelas N | Director | AWARD | 1,505 | — | — |
| Jun 9, 2026 | Minor Lloyd | Director | AWARD | 1,505 | — | — |
| Jun 9, 2026 | Pangalos Menelas N | Director | EXERCISE | 2,370 | — | — |
| Jun 9, 2026 | Patolawala Monish D | Director | AWARD | 1,505 | — | — |
| Jun 9, 2026 | LANGER SUSAN | Director | AWARD | 1,505 | — | — |
| Jun 9, 2026 | Mantas Jesus B | Director | AWARD | 1,505 | — | — |
Congressional trades
BIIB trades disclosed by members of Congress, with disclosure delay.
3 members · 2 buys / 2 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Kevin Hern | R | HOUSE | SELL | $1,001 - $15,000 | Biogen Inc | Sep 2, 2026(16d) |
| Jun 5, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | Biogen Inc | Jul 3, 2026(29d) |
| Jun 2, 2026 | Maria Elvira Salazar | R | HOUSE | SELL | $15,001 - $50,000 | Biogen Inc | Jul 8, 2026(37d) |
| Jan 30, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | Biogen Inc | Feb 16, 2026(18d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for BIIB.
Shares short
5,817,797
Settlement Sep 15, 2026
Change vs prior
+1.6%
Semi-monthly cycle
Days to cover
7.6
At avg daily volume
Of shares outstanding
≈3.9%
Estimate — not % of float
All BIIB filing & press-release reports (25)
- UBS double upgrades NVDA to Buy — PT $225 (+21%)Apr 22, 2026
- Needham upgrades BIIB to Buy — PT $255 (+30.5%)Jun 8, 2026
- Truist Securities upgrades BIIB to Buy — PT $235 (+18%)Jul 13, 2026
- Wells Fargo double upgrades to Overweight with $250 PT — +41% upsideApr 20, 2026
- PRESS-RELEASE reportSep 4, 2026
- PRESS-RELEASE reportSep 3, 2026
- PRESS-RELEASE reportAug 6, 2026
- PRESS-RELEASE reportJul 14, 2026
- PRESS-RELEASE reportJul 13, 2026
- PRESS-RELEASE reportJun 17, 2026
- PRESS-RELEASE reportJun 4, 2026
- PRESS-RELEASE reportJun 1, 2026
- PRESS-RELEASE reportMay 21, 2026
- PRESS-RELEASE reportMay 14, 2026
- 8-K reportMay 14, 2026
- PRESS-RELEASE reportMay 14, 2026
- PRESS-RELEASE reportMay 8, 2026
- DEFA14A reportApr 28, 2026
- 8-K reportApr 21, 2026
- PRESS-RELEASE reportApr 20, 2026
- PRESS-RELEASE reportMar 31, 2026
- COURT-RULING reportMar 30, 2026
- PRESS-RELEASE reportMar 28, 2026
- PRESS-RELEASE reportMar 19, 2026
- 8-K reportMar 11, 2026